Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1533 ARTÍCULOS , VIENDO DEL 226 AL 240

Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts

Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort.

Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002. Epub 2017 Apr 17.

Iatrogenic systemic transthyretin amyloid deposits in a case with domino liver transplantation: an autopsy case study

Tsuda Y, Misumi Y, Ueda M, Tasaki M, Huang G, Masuda T, Suenaga G, Kinoshita Y, Obayashi K, Yamashita T, Ando Y.

Amyloid. 2017 Mar;24(sup1):125. doi: 10.1080/13506129.2017.1287071.

Ethical Considerations for Deep Brain Stimulation Trials in Patients with Early-Onset Alzheimer's Disease

Viaña JNM, Bittlinger M, Gilbert F.

J Alzheimers Dis. 2017;58(2):289-301. doi: 10.3233/JAD-161073.

Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications

Narayanan KB, Han SS.

Curr Protein Pept Sci. 2017 Aug 30;18(11):1141-1151. doi: 10.2174/1389203718666170424153109.

Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease

Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, Bachurin SO, Aliev G.

CNS Neurol Disord Drug Targets. 2017;16(6):677-685. doi: 10.2174/1871527316666170424114444.

Impact of Nutritional Supplementation and a Psychomotor Program on Patients With Alzheimer's Disease

Vicente de Sousa O, Soares Guerra R, Sousa AS, Pais Henriques B, Pereira Monteiro A, Amaral TF.

Am J Alzheimers Dis Other Demen. 2017 Sep;32(6):329-341. doi: 10.1177/1533317517705221. Epub 2017 Apr 26.

Deletion of exons 9 and 10 of the Presenilin 1 gene in a patient with Early-onset Alzheimer Disease generates longer amyloid seeds

Le Guennec K, Veugelen S, Quenez O, Szaruga M, Rousseau S, Nicolas G, Wallon D, Fluchere F, Frébourg T, De Strooper B, Campion D, Chávez-Gutiérrez L, Rovelet-Lecrux A.

Neurobiol Dis. 2017 Aug;104:97-103. doi: 10.1016/j.nbd.2017.04.020. Epub 2017 Apr 28.

Nanoparticles as potential clinical therapeutic agents in Alzheimer's disease: focus on selenium nanoparticles

Nazıroğlu M, Muhamad S, Pecze L.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):773-782. doi: 10.1080/17512433.2017.1324781. Epub 2017 May 16.

Astrocyte dysfunction in Alzheimer disease

Acosta C, Anderson HD, Anderson CM.

J Neurosci Res. 2017 Dec;95(12):2430-2447. doi: 10.1002/jnr.24075. Epub 2017 May 3.

Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease

Xie J, Wang H, Lin T, Bi B.

Biomed Res Int. 2017;2017:2986460. doi: 10.1155/2017/2986460. Epub 2017 Apr 3.

Caregiver burden in Alzheimer-type dementia and psychosis: A comparative study from India

Sinha P, Desai NG, Prakash O, Kushwaha S, Tripathi CB.

Asian J Psychiatr. 2017 Apr;26:86-91. doi: 10.1016/j.ajp.2017.01.002. Epub 2017 Jan 17.

The Exceptional Vulnerability of Humans to Alzheimer's Disease

Walker LC, Jucker M.

Trends Mol Med. 2017 Jun;23(6):534-545. doi: 10.1016/j.molmed.2017.04.001. Epub 2017 May 5.

Can 8 months of daily tDCS application slow the cognitive decline in Alzheimer's disease? A case study

Bystad M, Rasmussen ID, Grønli O, Aslaksen PM.

Neurocase. 2017 Apr;23(2):146-148. doi: 10.1080/13554794.2017.1325911. Epub 2017 May 9.

Dysregulated Metabolism of the Amyloid-β Protein and Therapeutic Approaches in Alzheimer Disease

Kikuchi K, Kidana K, Tatebe T, Tomita T.

J Cell Biochem. 2017 Dec;118(12):4183-4190. doi: 10.1002/jcb.26129. Epub 2017 Jun 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias